MedPath

Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes

Phase 3
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Registration Number
NCT01960179
Lead Sponsor
Sanofi
Brief Summary

Primary Objective:

To assess the overall safety of lixisenatide once daily treatment in monotherapy over 24 and 52 weeks in patients with type 2 diabetes in Japan

Secondary Objective:

To assess the effects of lixisenatide once daily treatment in monotherapy over 24 and 52 weeks on:

* HbA1c (Glycated hemoglobin A1c) reduction;

* Fasting plasma glucose;

* Body weight.

Detailed Description

* Group 1: 60 weeks ± 11 days

* Group 2: 32 weeks ± 7 days

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
361
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
lixisenatidelixisenatide AVE0010lixisenatide monotherapy by group (Group 1: 52-week treatment; Group 2: 24-week treatment)
Primary Outcome Measures
NameTimeMethod
Safety over 24 and 52 weeks assessed by treatment emergent adverse event (TEAE), vital signs, 12-lead electrocardiogram (ECG), and laboratory data.from baseline to 24 weeks and 52 weeks
Secondary Outcome Measures
NameTimeMethod
Absolute change in body weightfrom baseline to week 24 and week 52
Absolute change in HbA1cfrom baseline to week 24 and week 52
Absolute change in fasting plasma glucosefrom baseline to week 24 and week 52

Trial Locations

Locations (30)

Investigational Site Number 392009

🇯🇵

Kisarazu-Shi, Japan

Investigational Site Number 392001

🇯🇵

Shinjuku-Ku, Japan

Investigational Site Number 392015

🇯🇵

Chuo-Ku, Japan

Investigational Site Number 392003

🇯🇵

Chuoh-Ku, Japan

Investigational Site Number 392007

🇯🇵

Koriyama-Shi, Japan

Investigational Site Number 392025

🇯🇵

Nagoya-Shi, Japan

Investigational Site Number 392030

🇯🇵

Sapporo-Shi, Japan

Investigational Site Number 392005

🇯🇵

Chiba-Shi, Japan

Investigational Site Number 392004

🇯🇵

Chuo-Ku, Japan

Investigational Site Number 392013

🇯🇵

Ogawa-Machi, Hikigun, Japan

Investigational Site Number 392022

🇯🇵

Okawa-Shi, Japan

Investigational Site Number 392019

🇯🇵

Yokohama-Shi, Japan

Investigational Site Number 392017

🇯🇵

Toshima-Ku, Japan

Investigational Site Number 392012

🇯🇵

Ebina-Shi, Japan

Investigational Site Number 392020

🇯🇵

Suita-Shi, Japan

Investigational Site Number 392006

🇯🇵

Adachi-Ku, Japan

Investigational Site Number 392011

🇯🇵

Mitaka-Shi, Japan

Investigational Site Number 392026

🇯🇵

Nagoya-Shi, Japan

Investigational Site Number 392014

🇯🇵

Ohta-Ku, Japan

Investigational Site Number 392018

🇯🇵

Sendai-Shi, Japan

Investigational Site Number 392024

🇯🇵

Higashiosaka-Shi, Japan

Investigational Site Number 392002

🇯🇵

Koganei-Shi, Japan

Investigational Site Number 392016

🇯🇵

Yokohama-Shi, Japan

Investigational Site Number 392028

🇯🇵

Osaka-Shi, Japan

Investigational Site Number 392023

🇯🇵

Kashiwara-Shi, Japan

Investigational Site Number 392008

🇯🇵

Kawagoe-Shi, Japan

Investigational Site Number 392021

🇯🇵

Osaka-Shi, Japan

Investigational Site Number 392010

🇯🇵

Chiyoda-Ku, Japan

Investigational Site Number 392027

🇯🇵

Toyonaka-Shi, Japan

Investigational Site Number 392029

🇯🇵

Osaka-Shi, Japan

© Copyright 2025. All Rights Reserved by MedPath